Top

Published in:

01-06-2021 | Sarcoidosis | ORIGINAL ARTICLE

Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET

Authors: Atsushi Yamamoto, MD, Michinobu Nagao, MD, Eri Watanabe, MD, Yasutaka Imamura, MD, Atsushi Suzuki, MD, Kenji Fukushima, MD, Kiyoe Ando, MD, Risako Nakao, MD, Akiko Sakai, MD, Mitsuru Momose, MD, Shuji Sakai, MD, Nobuhisa Hagiwara, MD

Published in: Journal of Nuclear Cardiology | Issue 3/2021

Abstract

Background

We analyzed ¹⁸F-Fludeoxyglucose positron emission tomography (FDG-PET) and ¹²³I-betamethyl-p-iodophenyl-pentadecanoic acid (BMIPP) single-photon emission computed tomography (SPECT) performed for cardiac sarcoidosis (CS) patients taking prednisolone, identified recurrence by FDG-PET, and investigated BMIPP as a recurrence and prognostic factor in CS.

Methods and Results

CS patients who underwent BMIPP and FDG-PET within 2 months were enrolled. The recurrence-free group included patients with standardized uptake value (SUVmax) < 4 in the myocardium consecutively for ≥ 2 years. The total BMIPP SPECT defect score (BDS) was used to estimate myocardial damage. The predictability of the initial BDS and SUVmax for major adverse cardiac events (MACE) was analyzed using Kaplan–Meier analysis. Overall, 73 patients and 250 BMIPP and FDG-PET sets were analyzed retrospectively (mean follow-up, 3.5 years). The BDS was significantly greater for the recurrence group (N = 21) vs recurrence-free group (20 ± 13 vs 14 ± 12, P = 0.041). Patients with BDS ≥16 had a significantly higher MACE rate than patients with BDS < 16 (log-rank test, P = 0.016). However, MACE occurrence was comparable between patients with SUVmax ≥ 4 and < 4.

Conclusions

BDS is a predictive marker of recurrence and MACE. SUV is not related to MACE. Recurrence, defined by prednisolone treatment-induced SUV variability, was observed in approximately 30% of CS patients.

Available only for authorised users

Kouranos V, Tzelepis GE, Rapti A, Mavrogeni S, Aggeli K, Douskou M et al (2017) Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC Cardiovasc Imaging 10:1437-47CrossRef

Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T et al (2001) Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88:1006-10CrossRef

Vita T, Okada DR, Veillet-Chowdhury M, Bravo PE, Mullins E, Hulten E et al (2018) Complementary value of cardiac magnetic resonance imaging and positron emission tomography/computed tomography in the assessment of cardiac sarcoidosis. Circ Cardiovasc Imaging 11:e007030CrossRef

Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA et al (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120:1969-77CrossRef

Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M et al (2008) Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 133:1426-35CrossRef

Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U et al (2013) CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 6:501-11CrossRef

Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K (2014) Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 146:1064-72CrossRef

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al (2014) Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 63:329-36CrossRef

Maruoka Y, Nagao M, Baba S, Takuro I, Kitamura Y, Kawanami S et al (2015) Evaluation of response to steroid therapy for cardiac sarcoidosis using volumetric analysis of 18F-FDG PET/CT. J Bioanal Biomed 09:229-34CrossRef

10.

Nanasato M, Hirayama H, Ando A, Isobe S, Nonokawa M, Kinoshita Y et al (2004) Incremental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging 31:1512-21CrossRef

11.

Chikamori T, Fujita H, Nanasato M, Toba M, Nishimura T (2005) Prognostic value of I-123 15-(p-iodophenyl)-3-(R, S) methylpentadecanoic acid myocardial imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol 12:172-78CrossRef

12.

Momose M, Fukushima K, Kondo C, Serizawa N, Suzuki A, Abe K et al (2015) Diagnosis and detection of myocardial injury in active cardiac sarcoidosis—Significance of myocardial fatty acid metabolism and myocardial perfusion mismatch. Circ J 79:2669-76CrossRef

13.

JCS Joint Working Group (2011) Guidelines for diagnosis and treatment of myocarditis (JCS 2009): Digest version. Circ J 75:734-43CrossRef

14.

Terasaki F, Azuma A, Anzai T, Ishizaka N, Ishida Y, Isobe M et al (2019) JCS 2016 guideline on diagnosis and treatment of cardiac sarcoidosis – digest version. Circ J 83:2329-88CrossRef

15.

Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K et al (2014) Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med 28:393-03CrossRef

16.

Ballul T, Borie R, Crestani B, Daugas E, Descamps V, Dieude P et al (2019) Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs. Int J Cardiol 276:208-11CrossRef

17.

Yokoyama R, Miyagawa M, Okayama H, Inoue T, Miki H, Ogimoto A et al (2015) Quantitative analysis of myocardial 18F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. Int J Cardiol 195:180-87CrossRef

18.

Hashimoto H, Nakanishi R, Mizumura S, Hashimoto Y, Okamura Y, Kiuchi S et al (2018) Prognostic value of (123)I-BMIPP SPECT in patients with nonischemic heart failure with preserved ejection fraction. J Nucl Med 59:259-65CrossRef

19.

Yamamichi Y, Kusuoka H, Morishita K, Shirakami Y, Kurami M, Okano K et al (1995) Metabolism of iodine-123-BMIPP in perfused rat hearts. J Nucl Med 36:1043-50PubMed

20.

Tanaka T, Okamoto F, Sohmiya K, Kawamura K (1997) Lack of myocardial iodine-123 15-(p-iodiphenyl)-3-R, S-methylpentadecanoic acid (BMIPP) uptake and CD36 abnormality—CD36 deficiency and hypertrophic cardiomyopathy. Jpn Circ J 61:724-25CrossRef

21.

Fujibayashi Y, Yonekura Y, Takemura Y, Wada K, Matsumoto K, Tamaki N et al (1990) Myocardial accumulation of iodinated beta-methyl-branched fatty acid analogue, iodine-125-15-(p-iodophenyl)-3-(R, S)methylpentadecanoic acid (BMIPP), in relation to ATP concentration. J Nucl Med 31:1818-22PubMed

22.

Fujibayashi Y, Nohara R, Hosokawa R, Okuda K, Yonekura Y, Tamaki N et al (1996) Metabolism and kinetics of iodine-123-BMIPP in canine myocardium. J Nucl Med 37:757-61PubMed

23.

Hosokawa R, Nohara R, Fujibayashi Y, Okuda K, Ogino M, Hata T et al (1997) Myocardial kinetics of iodine-123-BMIPP in canine myocardium after regional ischemia and reperfusion: Implications for clinical SPECT. J Nucl Med 38:1857-63PubMed

24.

Rosenthal DG, Parwani P, Murray TO, Petek BJ, Benn BS, De Marco T et al (2019) Long-term corticosteroid-sparing immunosuppression for cardiac sarcoidosis. J Am Heart Assoc 8:e010952CrossRef

25.

Shohei K, Mitsuru M, Kenji F, Naoki S, Atsushi S, Chisato K et al (2017) Regional myocardial damage and active inflammation in patients with cardiac sarcoidosis detected by non-invasive multi-modal imaging. Ann Nucl Med 31:135-43CrossRef

Title: Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET
Authors: Atsushi Yamamoto, MD
Michinobu Nagao, MD
Eri Watanabe, MD
Yasutaka Imamura, MD
Atsushi Suzuki, MD
Kenji Fukushima, MD
Kiyoe Ando, MD
Risako Nakao, MD
Akiko Sakai, MD
Mitsuru Momose, MD
Shuji Sakai, MD
Nobuhisa Hagiwara, MD
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Sarcoidosis
Sarcoidosis
Positron Emission Tomography
Prednisolone
Published in: Journal of Nuclear Cardiology / Issue 3/2021
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-021-02567-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognosis and recurrence in cardiac sarcoidosis: Serial assessment of BMIPP SPECT and FDG-PET

Abstract

Background

Methods and Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods and Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2021

18F-Fluorodeoxyglucose PET imaging in aortic graft infection: many more questions than answers

Regadenoson myocardial perfusion imaging predicts prognosis in patients with either left bundle branch block or a ventricular paced rhythm

New approach for quantification of left ventricular function from low-dose gated bloodpool SPECT: Validation and comparison with conventional methods in patients

BMIPP SPECT in cardiac sarcoidosis: A marker of risk?

Imagine, believe, and achieve

Leading by example: Experiences and lessons learned from ASNC’s Future Leaders of Nuclear Cardiology Symposium